NAD+ Patches: What the Evidence Supports

Nicotinamide adenine dinucleotide, universally shortened to NAD+, is a coenzyme that every cell in the body uses to run the reactions that turn food into usable energy. Levels of it decline with age, and that decline has become the basis for a booming market in supplements, IV drips and, more recently, transdermal patches. The patches are adhesive squares that claim to deliver NAD+ or its precursors through the skin and into the bloodstream over several hours. The honest position is this: the biology of NAD+ is well established, the delivery method is plausible in principle, and the clinical evidence that patches produce meaningful benefits in healthy people is thin. Anyone weighing up a purchase should understand which parts of the pitch rest on solid science and which rest on extrapolation.

Coffee drinkers already think about cellular energy, even if they would not put it that way. Caffeine works by blocking adenosine receptors, and adenosine is built from the same molecular family as NAD+. The parallel is not exact, but it explains why the language of energy metabolism travels so easily from the lab into consumer marketing. Agriculture has its own version of this story: a compound is identified as important, a deficiency is linked to decline, and a product appears promising to correct it. Sometimes that chain holds up. Sometimes it does not. NAD+ patches sit somewhere in the middle, and the useful thing a reader can do is learn to tell the difference.

What are NAD+ patches actually delivering?

Most patches on the market do not contain NAD+ itself. The molecule is large, charged and poorly suited to crossing the skin barrier intact. Instead, formulators typically use precursors such as nicotinamide riboside or nicotinamide mononucleotide, sometimes alongside nicotinic acid or nicotinamide. These are smaller and better studied as oral supplements. The patch format is an attempt to improve absorption by bypassing the digestive tract, where some precursors are broken down before they reach circulation.

Whether that attempt succeeds is the central question. Transdermal delivery works well for certain drugs, particularly ones that are lipid-soluble and potent at low doses. It works less predictably for water-soluble compounds that need to reach the bloodstream in large quantities. A patch that releases a precursor steadily over eight hours may produce very different blood levels from a capsule swallowed with breakfast, and not necessarily higher ones.

Why the skin barrier matters

The outermost layer of skin, the stratum corneum, is designed to keep things out. Formulators use penetration enhancers, liposomal carriers or iontophoresis to get around it. Each of these adds complexity, and each can affect how much of the active compound actually arrives where it is needed. Without published pharmacokinetic data for a specific patch, a buyer is guessing.

Does raising NAD+ levels actually produce benefits?

This is where the evidence gets interesting and where marketing tends to outrun it. NAD+ is genuinely required for mitochondrial function, DNA repair and the regulation of circadian rhythms. Animal studies have shown that restoring NAD+ levels in older mice can improve measures of metabolic health and physical performance. That work is real and has driven a great deal of legitimate scientific interest.

Human data is much more limited. Small trials of oral precursors have generally shown that they raise blood NAD+ levels safely, which is a meaningful finding in itself. What they have not consistently shown is that this translates into noticeable changes in how people feel or function. Some studies report modest effects on markers such as insulin sensitivity or inflammatory signalling. Others find nothing. The pattern is one of hints rather than conclusions, and the hints are stronger for people with specific deficiencies or conditions than for generally healthy adults.

• Raising NAD+ in the blood is achievable with several precursors.
• Raising it in tissues, particularly muscle and brain, is harder to demonstrate.
• Demonstrating a clinical benefit is harder still, and requires larger and longer trials.

Are patches better than capsules or IV drips?

Each route has trade-offs. Oral capsules are convenient and cheap but subject to first-pass metabolism in the liver. IV drips achieve high blood levels quickly but require a clinic visit and carry the usual risks of any infusion. Patches sit between the two: non-invasive, slow-release, and dependent on a delivery technology that varies enormously between products.

There is no published head-to-head trial showing that a patch outperforms an equivalent oral dose. That absence does not prove patches are ineffective, but it does mean the comparison is currently a matter of formulation quality rather than established fact. A well-designed patch with good penetration data may perform well. A poorly designed one may deliver almost nothing.

What should you check before buying?

The supplement and wellness market is lightly regulated in most countries, and patches are no exception. A few practical checks separate serious products from hopeful ones.

1. Ingredient disclosure. The label should state exactly which precursor is used and at what dose per patch, not per box.
2. Third-party testing. Independent certificates of analysis for purity and heavy metals are a basic quality signal.
3. Pharmacokinetic claims. If a seller claims a specific absorption rate, ask for the study. If none exists, treat the claim as marketing.
4. Adverse event reporting. Reputable sellers provide a way to report reactions. Skin irritation is the most commonly reported issue with any transdermal product.
5. Prescriber involvement. For higher-dose or injectable forms, a consultation with a licensed clinician is appropriate. Services that connect patients to prescribers, such as those offering NAD+ patches alongside clinical oversight, at least put a qualified professional between the buyer and the product.

Who should be cautious?

Anyone pregnant, breastfeeding, taking immunosuppressants, or managing cancer should speak to their own doctor before using any NAD+ product. Precursors interact with several biological pathways, and the long-term safety data in these groups is essentially absent. People with sensitive skin should patch-test on a small area first. And anyone hoping for a dramatic, fast result should recalibrate: the realistic expectation from current evidence is subtle at best, and possibly nothing at all.

Frequently asked questions

Do NAD+ patches work?

They may raise NAD+ levels if the formulation delivers the precursor effectively, but there is little published evidence that this produces noticeable benefits in healthy people. The mechanism is plausible; the outcome data is not yet there.

How long before you notice anything?

No reliable timeline exists in the literature. Some users report changes within days, others report none after weeks. Without controlled data, individual reports are difficult to interpret.

Are they safe?

Oral NAD+ precursors have generally been well tolerated in short trials. Transdermal use adds the risk of local skin reactions. Long-term safety data for patches specifically is limited, so a conversation with a clinician is sensible before starting.

The sensible summary is that NAD+ is a real and important molecule, that the decline in its levels with age is real, and that the products sold to address it are running ahead of the evidence. Patches are an interesting delivery format with genuine potential. They are not yet a proven intervention. Read the label, ask for data, and treat confident claims with the scepticism they have earned.

This article is part of an ongoing editorial series. Information current as of publication date.